Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2021)
21 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 25, 2021
Slide 1: AGM Chairman's Address and Investor Presentation (ASX Release)
ASX Release 25 November 2021 ASX code: PIQ AGM Chairman’s Address and Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to release a copy of the Chairman’s Address to be provided by Mr Terry Sweet and the Investor Presentation to be provi
Slide 2: Chairman's Address
Chairman’s Address Good Morning Ladies and Gentlemen My name is Terry Sweet, and as Chair of the company it is my pleasure to welcome you to the 7th Annual General Meeting of shareholders of Proteomics International Laboratories. It is now after 9:30 am, and as we have a quorum of shareholders prese
Slide 3: Proteomics International AGM Presentation
ASX: PIQ Proteomics International LABORATORIES LTD AGM Presentation 25 November 2021 Dr. Richard Lipscombe Managing Director
Slide 4: Disclaimer
Disclaimer ASX: PIQ ASX:PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associ
Slide 5: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ ASX:PIQ A medical technology company at the forefront of Corporate Snapshot – 19/11/2021 precision medicine and predictive diagnostics ASX code PIQ Share Price A$0.96 Diagnostics Shares on issue (+8.4m options) 105m PromarkerD Market Capitalisation
Slide 6: Board of Directors
Board of Directors ASX: PIQ Terry Sweet FAICD, Chairman (Retiring at 2021 AGM) ASX:PIQ Director of several listed companies over the past 30 years in both executive South & and non-executive capacities. Companies include XRF Scientific Ltd, where he was MD for 4 years, Western Biotechnology Ltd, Hea
Slide 7: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ ASX:PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 5
Slide 8: A new blood test for predicting diabetic kidney disease
ASX: PIQ ASX:PIQ A new blood test for predicting diabetic kidney disease 6
Slide 9: Problem & Solution
Problem & Solution ASX: PIQ ASX:PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the Roadblock onset of diabetic kidney disease The Problem • If unchecke
Slide 10: PromarkerD is Revenue Ready
PromarkerD is Revenue Ready ASX: PIQ The PromarkerD predictive test is poised to roll-out in markets globally ASX:PIQ Enormous Market ✓ 463m adults have diabetes globally: 1-in-3 currently have diabetic kidney disease (DKD) Peer reviewed publications – Clinical & analytical validity proven (Sensitiv
Slide 11: PromarkerD – Simple Integration & Utilisation
PromarkerD – Simple Integration & Utilisation ASX: PIQ ASX:PIQ Blood sample drawn Biomarkers analysed Results analysed by Results and intervention PromarkerD Hub software plan delivered Sample is drawn at clinic Laboratory uses a standard Cloud based algorithm, the Clinician delivers results or path
Slide 12: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention How PromarkerDTM results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Test every Low Risk • Standard diabetes management 12-2
Slide 13: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ PromarkerD significantly enhances diabetic kidney disease diagnosis and management ASX:PIQ Peer reviewed PromarkerD tested on over 5,000 patients in 4-year clinical studies PromarkerD predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney
Slide 14: PromarkerD Market Opportunity
PromarkerD Market Opportunity ASX: PIQ ASX:PIQ Diabetes incidence and Patent portfolio 50% undiagnosed Country Patent/Application No Patent Status No. Diabetics1 Australia 2011305050 Granted 1,288,300 Brazil BR112013006740 Granted 16,780,800 Canada 2811654 Granted 2,793,500 China ZL201180053583.9 Gr
Slide 15: PromarkerD – Route To Market
PromarkerD – Route To Market ASX: PIQ ASX:PIQ Diagnostic company / laboratory Laboratory conducts tests & submits raw Laboratory pays PIQ a royalty per license PromarkerDTM data to PromarkerD hub test Immunoassay kits PromarkerD Hub calculates ‘risk score’ manufactured and supplied and sends report
Slide 16: Diagnostics Pipeline
Diagnostics Pipeline ASX: PIQ ASX:PIQ Further Global Potential in New Markets ▪ Employs the Promarker™️ technology platform to develop novel intellectual property The Promarker™️ Research ▪ Targeting new diagnostic tests in areas of significant unmet need Pipeline & Timeline ▪ Enormous markets and r
Slide 17: In Development: Endometriosis
In Development: Endometriosis What is Endometriosis? • A debilitating condition in which tissue that normally lines the uterus grows outside the uterus (on the ovaries, fallopian tubes or the intestines) • The most common symptoms are chronic pain and menstrual irregularities • Diagnosis typically t
Slide 18: Timeline & Milestones
Timeline & Milestones ASX: PIQ 2021 Targets and Achievements 2021-22 targets ASX:PIQ 4 August 2021 Partnership with Royal 16 Nov 2021 23 April 2021 Women’s Hospital and Major licensing deals 10 June 2021 Board strengthened Univ. Melbourne targets for PromarkerD with Proteomics International Senior m
Slide 19: Value Inflection Points
Value Inflection Points ASX: PIQ ASX:PIQ Exceptional Global Share Price Catalysts 2021-22 Opportunity Milestone Qtr Dec’21 Mar’22 Jun’22 Sep’22 Dec’22 Impact ➢ Disruptive, cutting-edge technology & proven in-house PromarkerD diagnostics platform Licensing Deals Drive global uptake and future revenue
Slide 20: Peer Comparison
Peer Comparison ASX: PIQ ASX:PIQ Market Share FY21 FY21 Net Stock Code Company Focus Capitalisation Price Revenue Profit/Loss DKD test based on AI and a combination of predictive blood-based biomarkers, genetic RENX.LSE factors and electronic health records. ~A$965m 735p ~A$2.1m ~A$43m loss Renalyti
Slide 21: Contact
Contact ASX: PIQ ASX:PIQ Dr Richard Lipscombe Kyle Moss Managing Director Corporate Advisor T: +61 8 9389 1992 Euroz Hartleys E: enquiries@proteomicsinternational.com T: +61 9488 1400 www.proteomicsinternational.com E: kmoss@eurozhartleys.com Dirk van Dissel Investor Relations & Corporate Advisor Ca
Proteomics International Laboratories — Shareholder Meeting (November 2021) on 6ix